All Clinical Trials in United Kingdom

A listing of 3097 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

United Kingdom

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

FCI in Post-operative Low Grade Gliomas

NCT06294418

Recruiting

The aim of this pilot study is to explore the utility of a new imaging technique, called Field Cycling Imaging (FCI), in postoperative low grade gliomas. The main question it aims to answer is if FCI can differentiate subtypes of low grade gliomas. Participants will have one FCI scan.

Gender:

ALL

Ages:

16 years and above

Trial Updated:

03/04/2024

Locations: Aberdeen Royal Infirmary, Aberdeen, Not set

Conditions: Glioma

Learn More ›

AF Ablation With High Power Short Duration RF

NCT05777551

Recruiting

This is a prospective, multi-center, research study designed to evaluate the safety and efficacy of pulmonary vein (PV) isolation with high power short duration radiofrequency energy in patients with paroxysmal/persistent atrial fibrillation (AF). Subjects with paroxysmal/persistent AF will undergo catheter ablation using commercially approved devices (mapping system and catheters). Patients will be followed up for 12 months to measure the recurrence of AF and its predictors. The primary endpo... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

03/02/2024

Locations: Centre Cardiologique Du Nord, Paris, Not set +8 locations

Conditions: Atrial Fibrillation, Catheter Ablation

Learn More ›

ADIE-FS - Aligning Dimensions of Interoceptive Experience in Patients With Functional Seizures

NCT06105996

Recruiting

Functional seizures are common and harmful. They look like epileptic seizures but are not caused by the excess electrical discharges in the brain that arise in epilepsy. Our understanding of the mechanisms that give rise to functional seizures is limited, and for this reason the development of novel treatments for functional seizures is also limited. Recent research by our and other groups has shown that interoception may play an important role in the development of functional seizures. Interoce... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/01/2024

Locations: Queen Square Institute of Neurology, London, Not set

Conditions: Psychogenic Nonepileptic Seizures, Dissociative Seizures, Psychogenic Pseudoseizure, Functional Neurological Disorder, Non Epileptic Seizure

Learn More ›

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

NCT06298955

Recruiting

The purpose of this study is to assess the long-term safety and tolerability of repeat-dose OMS906 5 mg/kg IV administration at 8-week intervals in patients with PNH.

Gender:

ALL

Ages:

Between 18 years and 99 years

Trial Updated:

03/01/2024

Locations: Omeros Investigational Site, Aachen, Not set +4 locations

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Learn More ›

An Intervention Study Using HMOs to Improve IBS Symptoms

NCT06281600

Recruiting

There is now strong evidence implicating the human gut microbiota in many gastrointestinal diseases, including irritable bowel syndrome (IBS). Importantly, this enteric population is susceptible to dietary intervention and represents an exciting target for the prevention and treatment of gut mediated disorders. This study will investigate microbial components and activities associated with the gut microbiome, using a global systems biology approach to explore the capacity of a human milk carbohydrate intervention in modulating this microbial community to target IBS, with the primary objective of improving IBS symptoms. IBS is a highly prevalent gastrointestinal (GI) disorder with significant negative impact on quality of life of patients and high healthcare costs. Although prognosis of IBS is benign, it is a disorder that poses a considerable burden on the individual sufferer and society. Patients typically present with chronic abdominal pain and an altered bowel habit, frequently accompanied by bloating and distension. Often, IBS will afflict sufferers for life, with flares of activity followed by periods of remission. Incidence commonly peaks in the third and fourth decades of life. IBS is suggested to be a disorder of gut-brain interaction, and alterations of the microbiota-host interactions at the mucosal border may cause symptoms such as those previously mentioned. Therefore, microbiota-targeted interventions may benefit some people with IBS by beneficially modulating the gut microbiome. Several studies have confirmed that prebiotics, such as galactooligosaccharides (GOS), are able to successfully stimulate gut bifidobacteria and alleviate symptoms in IBS. Prebiotics are defined as "a substrate that is selectively utilised by host microorganisms conferring a health benefit" \[8\]. These studies suggest that prebiotics may have potential as therapeutic agents in IBS. Breastmilk is known to play a crucial role in the development of infants, providing key nutrients and immunological compounds important for initial protection against pathogens \[9\]. Among these compounds, human milk oligosaccharides (HMOs) represent the third most important component of breastmilk after lipids and lactose. HMOs have also been investigated for potential health benefits in adults, including their potential role as prebiotics for improved gut microbiota modulation. Studies looking specifically at HMO interventions in humans with IBS are sparse. These include a phase II, parallel, RCT in 58 IBS volunteers by Iribarren et al. and an open-label trial with 245 IBS participants from 17 sites across USA by Palsson et al.. None have been sufficiently powered to a degree which could influence clinical practice, but crucially tolerability and safety profiles of HMOs investigated, to date, have been consistently high. Using the global systems biology approach not yet applied to this research question, a pre-competitive approach to selecting a candidate HMO, and a crossover feasibility trial design, the investigators hope to forge a new direction in establishing the merits of HMO use in IBS. This study will look specifically at patients with all IBS subtypes, an area where there is a real therapeutic gap and clinical need for safe, effective therapy to improve quality of life. Participants will be randomly allocated to be given either the HMO or a placebo, with neither the patient nor the researchers knowing which they are receiving (randomised and double blind design). They will take this HMO or placebo for 28 days (randomly distributed), and then stop taking it in a 'washout' period of 28 days, allowing the gut microbiota to return to baseline. Then, the participants will take the other intervention (placebo or prebiotic, whichever they did not take in the first half of the study) for 28 days, then have a further washout period of 14 days. The study will then be over. With this proposal, the aim is to explore how HMOs affect the gut microbiota and whether they can do so in a manner that positively influences patients with IBS. The investigators also hope to develop molecular profiling as part of a research toolkit for gut microbiome-based HMO supplement studies. Read Less

Gender:

ALL

Ages:

Between 18 years and 60 years

Trial Updated:

02/27/2024

Locations: The University of Reading, Reading, Berkshire

Conditions: Irritable Bowel Syndrome

Learn More ›

Continuation Of a Study to Investigate the Effect of Thoracocentesis on Neural Respiratory Drive in Pleural Effusion

NCT05945043

Recruiting

The aim of this study is to better understand the relationship between pleural effusions and breathlessness in patients with unilateral pleural effusions and breathlessness who require pleural fluid removal for its management.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2024

Locations: Guy's & St Thomas' NHS Foundation Trust, London, Not set

Conditions: Pleural Effusion

Learn More ›

Determination of Utility of Intergluteal Cleft as Landmark for Neuraxial Midline in Obstetrics

NCT05983029

Recruiting

Our aim is to investigate whether a novel landmark, the groove between the buttocks or the intergluteal cleft, can facilitate the identification of the neuraxial midline in obstetric patients when compared to ultrasound as the reference standard for the determination of this midline

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/27/2024

Locations: Guy's Hospital, Great Maze Pond, London, Not set

Conditions: Obstetric Anesthesia Problems

Learn More ›

IMV to Accelerate Recovery of Lung Function in Veno-venous Extracorporeal Membrane Oxygenation; Lung Rest Or Moderate Mechanical Ventilation in ECMO

NCT06006676

Recruiting

Feasibility trial to inform a future multicentre randomized control trial. The investigators aim to evaluate the feasibility of a trial of near apnoeic ventilation (two breaths per minute) compared with standard ventilation (respiratory rate between 10 and 30 breaths) for patients with acute respiratory distress syndrome (ARDS) supported with veno-venous extracorporeal membrane oxygenation (V-V ECMO). Additionally, when a patient is determined as ready to wean from ECMO the investigators will ex... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2024

Locations: Guys & St. Thomas' NHS Foundation Trust, London, Not set

Conditions: ARDS

Learn More ›

Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung

NCT06144476

Recruiting

There are over 700,000 UK hospital admissions every year with lung disease symptoms. Two of the most common lung diseases contributing to these numbers are asthma and chronic obstructive pulmonary disease (COPD). The immunopathology of these diseases is not fully understood. Matched samples from the respiratory tract and circulation will be used to identify immune patterns throughout the respiratory system to elucidate the immunopathology of airway disease.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2024

Locations: Guy's & St Thomas' NHS Foundation Trust, London, Not set

Conditions: COPD, Asthma, Airway Disease

Learn More ›

Red Light Ptosis Proof-of-Concept

NCT06292182

Recruiting

This study tests a new treatment to help with droopy eyelids (ptosis) and eye movement problems (squint) in children and young people with genetically confirmed mitochondrial conditions - using red-light. We use a torch to shine a red light through the closed eyelid for 3 minutes a day. The study will run for 18 months. We believe that this treatment could help strengthen the muscle in the eyelid to make it easier to open the eyes, and could also help some children with squint.

Gender:

ALL

Ages:

Between 3 years and 18 years

Trial Updated:

02/27/2024

Locations: Moorfields Eye Hospital NHS Foundation Trust, London, Not set

Conditions: Mitochondrial Diseases, Blepharoptosis

Learn More ›

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

NCT01574053

Recruiting

Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and b... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/26/2024

Locations: University of Alabama, Birmingham, Alabama +182 locations

University of Alabama, Birmingham, Alabama

St. Joseph's Hospital and Medical Center, Phoenix, Arizona

University of California - Irvine Medical Center, Irvine, California

Loma Linda Medical Center, Loma Linda, California

University of California - Los Angeles, Los Angeles, California

University of California - Davis, Sacramento, California

University of California - San Diego, San Diego, California

University of California - San Francisco, San Francisco, California

Cenexel Rocky Mountain Clinical Research, LLC, Englewood, Colorado

University of Connecticut, Farmington, Connecticut

Georgetown University, Washington, District of Columbia

University of Florida Board of Trustees, Gainesville, Florida

University of Miami, Miami, Florida

University of South Florida, HDSA Center of Excellence at USF, Tampa, Florida

Emory University, Wesley Woods Health Center, Atlanta, Georgia

Georgia Health Sciences University, Augusta, Georgia

Northwestern University, Chicago, Illinois

University of Chicago, Chicago, Illinois

Rush University Medical Center, Chicago, Illinois

University of Illinois College of Medicine at Rockford, Rockford, Illinois

Indiana University, Indianapolis, Indiana

University of Iowa, Iowa City, Iowa

University of Kansas Medical Center, Kansas City, Kansas

Hereditary Neurological Disease Center, Wichita, Kansas

University of Louisville, Louisville, Kentucky

University of Maryland School of Medicine, Baltimore, Maryland

Johns Hopkins University, Baltimore, Maryland

Boston University Medical Center, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

University of Michigan, Ann Arbor, Michigan

Wayne State University, Detroit, Michigan

Hennepin County Medical Center, Minneapolis, Minnesota

Washington University in St. Louis, Saint Louis, Missouri

University of Nebraska Medical Center, Omaha, Nebraska

Cleveland Clinic - Las Vegas, Las Vegas, Nevada

Cooper University Hospital, Camden, New Jersey

Rutgers, the State University of New Jersey, New Brunswick, New Jersey

Albany Medical College, Albany, New York

Columbia University, New York, New York

University of Rochester, Rochester, New York

Duke University, Durham, North Carolina

Wake Forest School of Medicine, Winston-Salem, North Carolina

Sanford Health, Fargo, North Dakota

University of Cincinatti, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

The Ohio State University, Columbus, Ohio

Oregon Health and Science University, Portland, Oregon

University of Pennsylvania, Philadelphia, Pennsylvania

University of Pittsburgh, Pittsburgh, Pennsylvania

University of South Carolina, Columbia, South Carolina

University of Tennessee Health Science Center, Memphis, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Baylor College of Medicine, Houston, Texas

University of Texas Health Science Center, Houston, Texas

University of Utah, Salt Lake City, Utah

University of Vermont, Burlington, Vermont

University of Virginia, Charlottesville, Virginia

Virginia Commonwealth University Parkinson's and Movement Disorders Center, Henrico, Virginia

Virginia Commonwealth University, Richmond, Virginia

Booth Gardner Parkinson's Care Center (Evergreen Health), Kirkland, Washington

University of Washington Medical Center, Seattle, Washington

University of Wisconsin - Madison, Madison, Wisconsin

Instituto de Neurociencias Buenos Aires (INEBA), Buenos Aires, Not set

Westmead Hospital, Westmead, New South Wales

Monash University, Melbourne, Victoria

The Neurosciences Unit - North Metropolitan Hospital, Perth, Western Australia

University of Melbourne, Royal Melbourne Hospital, Parkville, Not set

Universitatsklinik Innsbruck, Innsbruck, Not set

University Hospitals Leuven, Leuven, Vlaams-Brabant

Bruxelles - Erasme, Bruxelles, Not set

Institut de Pathologie et de Génétique (IPG), Charleroi, Not set

Hôpital du Beau Vallon ASBL, Saint-Servais, Not set

University of Calgary, Movement Disorders Program, Calgary, Alberta

University of Alberta (Glenrose), Edmonton, Alberta

University of Alberta Hospital in Edmonton, Edmonton, Alberta

University of British Columbia, Vancouver, British Columbia

Nova Scotia Health Authority, Halifax, Nova Scotia

Centre for Movement Disorders, Markham, Ontario

The Ottawa Hospital, Ottawa, Ontario

North York General Hospital, Toronto, Ontario

CHUM Hospital of Notre Dame, Montreal, Quebec

CETRAM, Santiago, Not set

Universidad de Antioquia, Grupo de Neurociencias, Medellín, Antioquia

Servicios Médicos MS, Clínica de Marly, Bogotá, Cundinamarca

University Hospital of Aarhus, Aarhus, Not set

University Hospital of Copenhagen, Copenhagen, Not set

University Hospital of Odense, Odense, Not set

Hôpitaux Universitaires de Strasbourg Hôpital de Hautepierre-Service de Neurologie, Strasbourg, Alsace Lorraine

CHU Amiens-Picardie, Amiens, Not set

CHU Angers, Centre de Référence Maladies Neurogénétiques, Angers, Not set

Bordeaux - Huntington Disease competencies center, Bordeaux, Not set

CHU Gabriel-Montpied, Clermont-Ferrand, Not set

Hôpital Henri Mondor, Centre d'Investigation Clinique, Créteil, Not set

Lille-Amiens - Huntington Disease Constituent site, LILLE Cedex, Not set

Hôpital La Timone, Marseille, Not set

CHU Montpellier, Montpellier, Not set

Institut du Cerveau et de la Moelle Epinière, Paris, Not set

Hôpital Purpan, Centre d'Investigation Clinique, Toulouse, Not set

University Hospital Aachen, Aachen, Not set

University of Berlin, Berlin, Not set

St. Josef und St. Elisabeth Hospital, Bochum, Not set

University Hospital Carl Gustav Carus Dresden, Dresden, Not set

University Hospital Erlangen, Erlangen, Not set

University Medical Center Freiburg, Freiburg, Not set

Paracelsus Elena Klinik Kassel, Kassel, Not set

University Hospital Schleswig-Holstein, Lübeck, Not set

University Hospital Giessen and Marburg, Marburg, Not set

Technical University of Munich, Munich, Not set

George-Huntington-Institut GmbH, Münster, Not set

kbo-Isar-Amper-Klinikum Taufkirchen (Vils), Taufkirchen, Not set

University Hopsital of Ulm, Ulm, Not set

University Hospital of Wuerzburg, Würzburg, Not set

Beaumont Hospital, Dublin 9, Republic Of Ireland

Fondazione IRCCS Istituto Neurologico Carlo Besta - Genetics, Milan, MI

Bari Policlinico General Hospital, Bari, Not set

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Not set

Università degli Studi di Genova (DINOGMI), Genoa, Not set

Fondazione IRCCS Istituto Neurologico Carlo Besta - Neurology, Milan, Not set

University of Naples, Napoli, Not set

Università Cattolica del Sacro Cuore, Rome, Not set

Lega Italiana Ricerca Huntington (LIRH), Rome, Not set

Azienda Ospedaliera Sant'Andrea, Rome, Not set

University Medical Center Groningen, Groningen, Not set

Leiden University Medical Centre, Leiden, Not set

Clinical Trial Center Maastricht B.V., Maastricht, Not set

Auckland City Hospital, Auckland, Not set

New Zealand Brain Research Institute at University of Otago, Christchurch, Not set

Wellington Hospital, Wellington, Not set

Copernicus Podmiotem Leczniczym sp. z o.o., Gdansk, Not set

Krakowska Akademia Neurologii Sp. z o.o, Katowice, Not set

Krakow - Krakowska Akademia Neurologii, Kraków, Not set

Solumed Centrum Medyczne, Poznan, Not set

Medical University of Warsaw, Warsaw, Not set

Institute of Psychiatry and Neurology, Warsaw, Warsaw, Not set

Hospital Prof Doutor Fernando Fonseca, Amadora, Not set

Hospital Universitário de Coimbra, Coimbra, Not set

Central Lisbon Hospital, Lisbon, Not set

Hospital de Santa Maria / Instituto de Medicina Molecular, Lisbon, Not set

Hospital Universitário de São João, Porto, Not set

Hospital Infanta Cristina, Badajoz, Badajoz, Not set

Hospital de Cruces, Barakaldo, Not set

Hospital Universitari de Bellvitge, Barcelona,, Not set

Hospital de la Santa Creu i Sant Pau, Barcelona, Not set

Hospital Mare de Déu de la Mercè, Barcelona, Not set

Fundacion Clinic per a La Recerca Biomèdica, Barcelona, Not set

Hospital Universitario de Burgos, Burgos, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Fundación Jiménez Díaz, Madrid, Not set

Hospital Son Espases, Palma De Mallorca, Not set

Complejo Hospitalario de Navarra, Pamplona, Not set

Fundacion Hospital Universitario La Fe, Valencia, Not set

Siloah AG, Gümligen, Not set

University Hospital Zurich, Zürich, Not set

Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon

Leicestershire Partnership, Narborough, Leicestershire

North Bristol NHS Trust, Bristol, UK

Fife Health Board, Kirkcaldy, UK

Betsi Cadwaladr University Health Board, Wrexham, UK

University of Aberdeen, Aberdeen, Not set

Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, Not set

University of Cambridge, Cambridge, Not set

Cardiff University, Cardiff, Not set

Tayside Health Board, Dundee, Not set

Lothian Health Board, Edinburgh, Not set

Greater Glasgow Health Board, Glasgow, Not set

Ayrshire Central Hospital, Kilmarnock, Not set

NHS Forth Valley, Larbert, Not set

Leeds Teaching Hospitals, Leeds, Not set

The Walton Centre, Liverpool, Not set

Guy's and St. Thomas's NHS Foundation Trust, London, Not set

St. George's Hospital, London, Not set

University College of London, London, Not set

Central Manchester University Hospitals NHS Foundation Trust, Manchester, Not set

Northumberland, Tyne & Wear NHS Foundation Trust of St. Nicholas Hospital, Newcastle-upon-Tyne, Not set

St. Andrews Healthcare, Northampton, Not set

Oxford Radcliffe Hospitals, Oxford, Not set

Plymouth Hospitals NHS Trust, Plymouth, Not set

Poole Hospital, Poole, Not set

Royal Berkshire NHS Foundation Trust, Reading, Not set

Sheffield Children's NHS Foundation Trust, Sheffield, Not set

University Hospital Southampton, Southampton, Not set

North Staffordshire Combined Healthcare NHS Trust, Stoke-on-Trent, Not set

Avon and Wiltshire Mental Health Partnership, Swindon, Not set

Conditions: Huntington's Disease

Learn More ›

Angelman Syndrome Natural History Study-FAST UK

NCT05100810

Recruiting

The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of Angelman syndrome (AS) in children and adults. This will be performed by acquiring baseline measurements, and developing effective outcome measures and diagnostic tools for the syndrome, to prepare the healthcare system for forthcoming clinical trials.

Gender:

ALL

Ages:

All

Trial Updated:

02/26/2024

Locations: University of Oxford, Oxford, Oxon

Conditions: Angelman Syndrome

Learn More ›